Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants Clinical Trial

Official title:

A Phase 1, Randomized, Double-blind, Single-dose, Partial Replicate, 3-period Cross-over Study to Assess the Total Systemic Exposure Bioequivalence of Budesonide and Albuterol Delivered by BDA MDI Hydrofluoroolefin (HFO) Compared With BDA MDI (Hydrofluoroalkene) HFA.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06139991
• Other study ID #: D6933C00001
• Status: Completed
• Phase: Phase 1
• Start date: November 16, 2023
• Est. completion date: May 4, 2024

Study information

• Verified date: May 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the Pharmacokinetic (PK) and safety of Budesonide and albuterol (BDA) metered dose inhaler (MDI) HFO and BDA MDI HFA in healthy male and female participants.

Description:

Eligible participant will receive 3 single-dose treatments; 2 doses of BDA MDI HFA and 1 dose of BDA MDI HFO.

• Treatment A: 2 inhalations, single dose of BDA MDI HFO 80/90 μg (test formulation)

• Treatment B: 2 inhalations, single dose of BDA MDI HFA 80/90 μg (reference formulation) Participants will be randomly assigned to receive any 1 of the 3 treatment sequences of ABB, BBA or BAB.

The study will comprise of:

• A screening period of maximum 28 days.

• Three Treatment periods will be up to approximately 22 days (including Follow-up).

• A final follow-up calls within 3-7 days after the last dose of study intervention.

Each participant has to be involved in the study for up to 48 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: May 4, 2024
• Est. primary completion date: May 4, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy male and female participants (of non-childbearing potential) aged 18 to 60 years, inclusive, with suitable veins for cannulation or repeated venipuncture.

• Female participants must have a negative pregnancy test at screening and on admission and must not be lactating.

• Participants with Body mass index between 18 and 30 kg/m^2, inclusive, and weighing between 50 kg and no more than 120 kg inclusive.

• Participants must have a Forced expiratory volume (FEV)1 = 80% of the predicted normal value and an FEV1/FVC> 70% regarding age, height, and ethnicity at the screening visit.

• Participants must demonstrate proper inhalation technique and is able to use an MDI properly after training.

Exclusion Criteria:

• History or presence of gastrointestinal, hepatic or renal disease, or any other clinically significant disease or disorder.

• History of any clinically significant disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.

• Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study drug.

• Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results at the screening.

• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, or Human immunodeficiency virus (HIV).

• Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG.

• Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening.

• Known or suspected history of alcohol or drug abuse.

• Positive screen for drugs of abuse, alcohol, or cotinine at screening.

• History or presence of severe allergy/hypersensitivity.

• Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of the study drug.

• Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of study drug.

• Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.

• Excessive intake of caffeine-containing drinks or food.

• Vulnerable participants.

Related Conditions & MeSH terms

• Heathy Participants

Intervention

Drug:
• Treatment A (BDA MDI HFO)
Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
• Treatment B (BDA MDI HFA)
Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.

Locations

Country	Name	City	State
United States	Research Site	Glendale	California

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)	The AUClast of budesonide and albuterol will be evaluated to assess the bioequivalence of the total systemic exposure of budesonide and albuterol administered.	Day 1, Day 2 (pre-dose and post-dose)
Primary	Maximum plasma drug concentration (Cmax)	The Cmax of budesonide and albuterol will be evaluated to assess the bioequivalence of the total systemic exposure of budesonide and albuterol administered.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Area under plasma concentration-time curve from time 0 to infinity (AUCinf)	The AUCinf after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Time to reach maximum observed concentration (Tmax)	The Tmax after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Terminal elimination half-life (T1/2?z)	The T1/2?z after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT)	The MRT after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Apparent total body clearance (CL/F)	The CL/F after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Apparent volume of distribution during the terminal phase (Vz/F)	The Vz/F after administration of budesonide and albuterol will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Ratio Maximum plasma drug concentration (Cmax)	The ratio of Treatment A (test formulation) and Treatment B (reference formulation) Cmax values will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Ratio Area under plasma concentration-time curve from time 0 to infinity (AUCinf)	The ratio of Treatment A (test formulation) and Treatment B (reference formulation) AUCinf values will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Ratio Are under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)	The ratio of Treatment A (test formulation) and Treatment B (reference formulation) AUClast values will be evaluated.	Day 1, Day 2 (pre-dose and post-dose)
Secondary	Number of participants with Adverse Events	The safety and tolerability of single doses of BDA MDI HFO and BDA MDI HFA will be evaluated.	From Screening (= 28 days to Day -2) until Follow-up phone call (within 3 to 7 days post final dose)